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Abstract
A simple, sensitive and accurate stability-indicating HPLC method has been developed and validated for
determination of varenicline (VRC) in its bulk form and pharmaceutical tablets. Chromatographic separation was
achieved on a Zorbax Eclipse XDB-C8 column (150 mm × 4.6 mm i.d., particle size 5 μm, maintained at ambient
temperature) by a mobile phase consisted of acetonitrile and 50 mM potassium dihydrogen phosphate buffer
(10:90, v/v) with apparent pH of 3.5 ± 0.1 and a flow rate of 1.0 ml/min. The detection wavelength was set at 235
nm. VRC was subjected to different accelerated stress conditions. The degradation products, when any, were well
resolved from the pure drug with significantly different retention time values. The method was linear (r = 0.9998)
at a concentration range of 2 - 14 μg/ml. The limit of detection and limit of quantitation were 0.38 and 1.11 μg/
ml, respectively. The intra- and inter-assay precisions were satisfactory; the relative standard deviations did not
exceed 2%. The accuracy of the method was proved; the mean recovery of VRC was 100.10 ± 1.08%. The proposed
method has high throughput as the analysis involved short run-time (~ 6 min). The method met the ICH/FDA
regulatory requirements. The proposed method was successfully applied for the determination of VRC in bulk and
tablets with acceptable accuracy and precisions; the label claim percentages were 99.65 ± 0.32%. The results
demonstrated that the method would have a great value when applied in quality control and stability studies for
VRC.
Background
Varenicline (VRC, Figure 1); 7,8,9,10-tetrahydro-6,10-
methano-6H-azepino[4,5-g]quinoxaline (2R,3R), is a
novel agent that is a centrally acting as a highly selective
partial agonist for the nicotinic acetylcholine receptor
[1]. VRC has mixed agonistic-antagonistic properties,
thus it has the therapeutic benefit of relieving the symp-
toms of nicotine withdrawal and cigarette craving during
abstinence while blocking the reinforcing effect of nico-
tine in those who lapse [2-4]. VRC tartrate (Champix
®
and Chantix
®; Pfizer) has been approved by the USA-
FDA as an aid to smoking cessation [5]. The approved
regime of VRC is 1 mg for 12 weeks, starting with a 1-
week titration period [6].
The quality of pharmaceutical product of VRC, in
terms of purity and stability of the active substance and/
or finished product is vital for the effective and safe
delivery of its therapeutic values to the smokers. This is
because the presence of impurities and/or potential
degradation products may cause changing of chemical,
pharmacological, and/or toxicological properties of the
active drug entity [7-9]. In general, pharmaceuticals are
sensitive to environmental factors such as temperature,
humidity, and light. These factors usually vary during
manufacturing, transportation, storage, and distribution
of the finished product. For these reasons, stability test-
ing of the active substance and the finished product is
necessary for providing information about potential
degradation products, possible degradation pathways of
the drug, compatibility of the drug with the excipients
in the finished product, and the long-term effects of the
environmental factors on the active drug and its finished
products. Results of stability testing are important in
developing proper manufacturing process, selecting
proper packaging, storage conditions, product’ss h e l f
life, and determining the expiration date [10-12].
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© 2011 Kadi et alFurthermore, the climate is widely varying worldwide,
and consequently, the quality of pharmaceutical product
of VRC is greatly affected by the change in the environ-
mental factors. As well, VRC-containing tablets are
imported from outside of many countries, consequently
there is a major concern about its quality after exposure
to transportation, storage, and other conditions. There-
fore, quality control for VRC-containing tablets is criti-
cally concerned in these countries. In literature, only
one report has been found describing the separation and
quantitation of process-related substances to VRC tarta-
rate [13], however there was no report on the stability-
indicating assay for VRC. For these reasons, a stability-
indicating method for determination of VRC in its bulk
drug and pharmaceutical tablets is essential, particularly,
such methods have become an important aspect of any
analytical method validation and a part of ICH guidance
for pharmaceutical industry [12].
The present study describes, for the first time, the
development and validation of a stability-indicating
HPLC method for stability evaluation and quantitative
determination of VRC in the presence of its degradation
products.
Results and Discussion
Method Development
The initial method development was conducted on pure
drug using working standardss o l u t i o np r o t e c t e df r o m
light. The light absorption characteristics of VRC are not
available in literature, therefore its ultraviolet (UV)-
absorption spectrum was recorded for selecting the
proper maximum absorption peak (lmax). As shown in
Figure 1, the lmax of VRC is located at 235 nm. There-
fore, the detection wavelength of the detector was set at
this wavelength. Actual chromatographic conditions were
established after number of preliminary experiments for
selecting the proper mobile system. Different mobile
phase systems were tested, and the selection of the
proper system depended on its ability to give good
separation between the pure VRC and its possible impu-
rities and/or degradation products. Acceptable separation
was achieved on Zorbax Eclipse XDB-C8 column (150
mm × 4.6 mm i.d., particle size 5 μm) using a mobile
phase composed by acetonitrile:0.05 M potassium mono-
basic phosphate buffer of pH 3.5 (10:90, v/v)p u m p e d
with a flow rate of 1 m/min. The column temperature
w a sk e p tc o n s t a n ta t2 5±2 ° C .U n d e rt h e s ec h r o m a t o -
graphic conditions, the run time of the sample was 6
min, and the retention time of VRC was 3.03 ± 0.06 min
(n = 3) (Figure 2A).
Method Validation
Linearity and Sensitivity
Using the above-mentioned optimum chromatographic
conditions, three independent calibration curves were
constructed correlating the detector signals with the
corresponding VRC concentrations. Each curve was gen-
erated by 7-concentration points; each concentration
was injected in triplicates). Regression analysis for the
results was carried out using the least-square method.
The standard deviation values of each concentration
point (triplicates) did not exceed 2%. The results
revealed a good linear calibration fit in the range of 2-
14 μg/ml. The calibration equation was: AU = - 4443 +
44599 C (r = 0.9998), where AU is the detector signal,
C is the concentration of VRC, and r is the correlation
coefficient. The high r value was indicative for the good
linearity, and the low values of standard deviations of
the intercept and the slope were indicative for the
Varenicline
N
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NH
Figure 1 Chemical structure of varenicline (VRC) and its
absorption spectrum against water. Concentration of VRC was 10
μg/ml in water.
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Figure 2 Representative chromatogram of 10 μg/ml of
standard solution of VRC (solid black tracing) and solution of
tablet extract containing nominal VRC concentration of 10 μg/
ml (dotted red tracing).
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structing the calibration curve.
The limit of detection (LOD) and limit of quantitation
(LOQ) were calculated based on the signal-to-noise
ratio [14]. The intercept was then equal to SD0 (the
estimated SD at a concentration of zero). LOD was then
defined as 3SD0, and LOQ was defined as 10SD0. The
LOD and LOQ values were 0.11 and 0.38 μg/ml,
respectively.
Precision
Precision was measured in accordance with ICH recom-
mendation. Five consecutive injections of VRC solution
at three varying concentrations (6, 8, and 10 μg/ml)
showed excellent repeatability (intra-day precision) as
the relative standard deviation (RSD) of the signal values
did not exceed 0.24% (Table 1). Inter-day precision
(reproducibility) was determined by measuring inter-day
variation for triplicate determination of VRC at the
same VRC concentrations (6, 8, and 10 μg/ml). The low
RSD values (≤ 0.34%) indicated the acceptable reprodu-
cibility of the method [14].
Accuracy
Accuracy was determined by the recovery study of
known amounts (6 - 12 μg/ml) of VRC standard added
to a placebo matrix for tablets. The samples were ana-
lyzed (5 replicates were injected) by one analyst, and the
added amounts were calculated from a calibration curve.
The recovery was presented as percentages, (calculated
concentration/nominal concentration × 100). The recov-
ery values ranged from 98.63 to 101.19 ( ± 0.22 -
0.55%), Table 2. These results indicated the acceptable
accuracy of the method [14].
Robustness and Ruggedness
In order to measure the extent of the method robust-
ness, the most critical parameters were interchanged
while keeping the other parameters unchanged, and in
parallel the chromatographic profile was observed and
recorded. The chromatographic parameters were inter-
changed within the range of 1-10% of the optimum
recommended conditions. The studied parameters were:
the composition of the mobile phase, pH, flow rate, and
column temperature. The results indicated that the
small change in the conditions did not significantly
affect the determination of VRC.
Ruggedness of the method was determined by using
mobile phase components from two different
manufactures. There was no significant change in the
retention time of VRC was observed; RSD was 0.24 -
0.37% indicating the ruggedness of the method.
Sample Solution Stability
The stability of the drug in solution during analysis was
determined by repeated analysis of samples during the
course of experimentation on the same day and also
after storage of the drug solution (8 μg/ml) for 24, 48
and 72 hours under laboratory bench condition (25 ± 1°
C) and under refrigeration (8 ± 0.5°C). There was no
significant change in analysis over a period of 72 hours.
The mean RSD between peak areas for the samples
stored under refrigeration (8 ± 1°C) and at laboratory
temperature (25 ± 1°C) was found to be 0.47% and
0.24%, respectively, suggesting that the drug solution
can be stored without any degradation over the time
interval studied.
System Suitability Tests
The chromatographic systems used for analysis must
pass the system suitability limits before sample analysis
can commence. The capacity factor (K), injection
repeatability (as described earlier in the subsection, pre-
cision), tailing factor (T), theoretical plate number (N)
and resolution (Rs) for the principle peak and its degra-
dation product were evaluated using VRC solution of 8
μg/ml. The capacity factor (K) was found to be 1.99
indicating that the VRC peak is well resolved with
respect to the void volume. The RSD of five consecutive
injections was found to be 0.24%, indicating good injec-
tion repeatability. The tailing factor (T) for VRC peak
was found to be 1.25, reflecting good peak symmetry.
The resolution (Rs) for the principle peak and degrada-
tion product was found to be 1.87, indicating good
separation of the drug from degradation product. The
theoretical plate number (N) was found to be 1179 for
the column used in the study (150 mm × 4.6 mm i.d.,
particle size 5 μm), thus demonstrating acceptable col-
umn efficiency. All these results assure the adequacy of
the proposed HPLC method for routine analysis of VRC.
Stability-Indicating Study
The ICH guideline entitled stability testing of drug sub-
stances and products [14] requires the stress testing to
be carried out to elucidate the inherent stability charac-
teristics of the active substance, and provide a rapid
identification of differences that might result from
Table 1 Precision of the proposed method
Concentration level (μg/ml) Intra-day precision Inter-day precision
Peak area (mean ± SD) RSD (%) Peak area (mean ± SD) RSD (%)
6 256980 ± 568.4 0.22 259606 ± 1588 0.61
8 351882 ± 1182 0.34 358161 ± 865.7 0.24
10 436126 ± 388.6 0.09 463025 ± 1316 0.28
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ple. Susceptibility to oxidation, hydrolytic, and photolytic
stability are the required tests. An ideal stability-indicat-
ing method is one that quantifies the standard drug alone
and also resolves its degradation products. As described
in the experimental section, different stress conditions
were applied: boiling, acid, base hydrolysis, oxidation,
and irradiation with UV light. From this investigation, it
was clear that in case of boiling, UV irradiation (solid
state and solution), and oxidation, VRC was stable under
the employed stress conditions as no degradation pro-
ducts were observed in their chromatograms, which were
identical to the chromatogram of VRC solution that has
not been subjected to any stress conditions (Figure 3A).
In case of acid hydrolysis and alkaline hydrolysis degrada-
tion products were observed at retention times of 1.46
and 1.37 min, respectively (Figure 3B-D). In both cases,
the method was able to separate completely the degrada-
tion products from the intact VRC. This confirmed the
selectivity and stability-indicating property of the pro-
posed method. The concentration of the produced degra-
dation products relative to the intact VRC was calculated
and found to be 0.29 and 0.31% in case alkaline hydroly-
sis and acid hydrolysis, respectively.
Applicability of the Method
It is evident from the results obtained previously that
the proposed method gave satisfactory results with the
analysis of VRC in bulk. Thus, VRC-containing tablets
were subjected to the analysis by the proposed method.
The label claim percentage was 99.7 ± 0.32%. This
acceptable value indicated the applicability of the
method for the routine quality control of VRC tablets
without interference from the excipients. This was evi-
denced from the good label claim percentage as well as
the absence of any peaks in the chromatogram of the
tablet extract solution (Figure 2).
Experimental
Materials
Varenicline Tartarate reference standard with claimed
purity of 99.6% was purchased from Weihua Pharma
Co. Ltd. (Zhejiang, China). Champix
® tablets (Pfizer Inc,
New York, USA), labeled to contain 1 mg (as the anhy-
drous base) per tablet was obtained from the local mar-
ket. HPLC-grade solvents, and reagent-grade sodium
hydroxide, hydrochloric acid, hydrogen peroxide, potas-
sium dihydrogen phosphate and orthophosphoric acid
Table 2 Evaluation of the method accuracy by recovery
study
Added concentration (μg/ml) Found concentration
(μg/ml ± SD)
Recovery
(% ± RSD)
a
6 5.92 ± 0.03 98.6 ± 0.55
8 8.01 ± 0.02 100.1 ± 0.22
10 10.05 ± 0.03 100.5 ± 0.30
12 12.14 ± 0.04 101.2 ± 0.33
a Values are mean of 5 determinations ± RSD.
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Figure 3 Stress testing of VRC. Panel A is VRC standard solution that
has not been subjected to any stress condition. Panels from B to D are
samples that have been subjected to acid hydrolysis, alkali hydrolysis,
oxidation, respectively. Red dotted tracing in panel D is the blank hydrogen
peroxide solution without VRC. Chromatograms of the samples that have
subjected to boiling and UV irradiation are identical with panel A.
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tilled water purified by a Millipore Milli-Q
® UF Plus
apparatus (Millipore, Molsheim, France) was used
throughout the work.
Chromatographic system
HPLC apparatus consisted of a Waters Alliance HPLC
systems (Waters, USA) equipped with 2996 photodiode
array (PDA) detector. The chromatographic separations
were performed on a Zorbax Eclipse XDB-C8 column
(150 mm × 4.6 mm i.d., particle size 5 μm) manufac-
tured by Millipore, USA. The column temperature was
kept constant at 25 ± 2°C. Separations were performed
in isocratic mode using a mobile phase consisted of
acetonitrile and 50 mM potassium dihydrogen phos-
phate buffer (10:90, v/v), and an apparent pH adjusted
to 3.5 ± 0.1 with 10% phosphoric acid solution. The
mobile phase was filtered by a Millipore vacuum filtra-
tion system equipped with a 0.45 μm filter, degassed by
ultrasonic bath, and by bubbling helium gas for 5 min
prior to its use. The flow rate of the mobile phase was 1
ml/min, and the sample injection volume was 10 μl.
The PDA detector was set at 235 nm. Peak identity was
confirmed by retention time comparison and compari-
son of the spectra obtained from the PDA detector.
Preparation of standard and sample solutions
An accurately weighed quantity (25 mg) of VRC refer-
ence standard material was transferred to a 25-ml volu-
metric flask, and dissolved in 25 ml water. This stock
solution (1 mg/ml) was further diluted with water to
produce a working standard solution of 8 μg/ml. Tablets
sample was prepared as the following: 20 tablets were
weighed and the average weight was calculated. Tablets
were crushed to a fine powder, and a quantity of the
powdered tablets, equivalent to 10 mg of VRC, was
transferred to 50 ml volumetric flasks. A 25 ml of
methanol was added, the contents of the flask were sha-
ken for 10 min by a mechanical shaker, and the volume
was diluted to 50 ml with methanol. This solution (0.5
mg/ml) was diluted to give a concentration 10 μg/ml.
This solution was filtered through a 0.45 μm membrane
filter and the filtrate was subjected to the analysis by the
proposed method.
Forced degradation
Boiling
One milliliter of VRC solution (25 mg/ml) was trans-
ferred to a small rounded flask. The solution was sub-
jected to reflux for 2 h in a boiling water bath. The
solution was cooled to room temperature (25 ± 5°C),
and a volume of 10 μl (1 mg sample) was injected into
the HPLC system.
Acid and alkali hydrolysis
Aliquot of 1 ml of VRC solution (25 mg/ml) was trans-
ferred to a small rounded flask. The solution was mixed
with 4 ml of 0.1 N hydrochloric acid, or 0.1 N sodium
hydroxide. The prepared solutions were subjected to
reflux for 2 h in a boiling water bath. The samples were
cooled to room temperature (25 ± 5°C), neutralized with
an amount of acid or base equivalent to that of the pre-
viously added. From the resulting neutral solution, 10 μl
(1 mg) was injected into the HPLC system.
Oxidation
One milliliter of VRC solution (25 mg/ml) was trans-
ferred to rounded flask. The contents were then mixed
with 4 ml of 30% hydrogen peroxide solution, and the
reaction mixture was allowed to proceed at room tem-
perature (25 ± 5°C) for 2 h with intermittent shaking. A
volume of 10 μl (1 mg) was injected into the HPLC
system
Irradiation with ultraviolet light
A sample powder of VRC (25 mg) was exposed to UV
light (245 nm) for 72 hours. The material was dissolved
in 5 ml water. The solution was filtered with syringe fil-
tration disk and diluted to 25 ml with suitable solvent
to obtain a claimed concentration of 1 mg/ml. A volume
of 10 μl was injected into the HPLC system. As well, an
aqueous solution of VRC (1 mg/ml) was exposed to UV
light (245 nm) for 72 hours, and then 10 μl was injected
into the HPLC system
Conclusions
The present study represents the first report that deals
with the development of a stability-indicating HPLC
method for determination of VRC. This study is a typi-
cal example of development of a stability-indicating
assay, established following the recommendations of
ICH/FDA guidelines. The proposed method showed
acceptable accuracy, precision, selectivity, and wide lin-
ear concentration range. From the economical point of
view, the method involved the native UV-absorbing
property of VRC, rather than expensive derivatizing ana-
lytical reagents. Statistical analysis for the results proved
that the method is suitable for the determination of
VRC in bulk and tablet forms without any interference
from the degradation products, and it is recommended
for routine use in quality control industry laboratories.
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